The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Evaluating Therapy With Encorafenib, Binimetinib, and Ribociclib in Melanoma

Paola A. Ascierto, MD
Published Online: 10:43 PM, Mon June 5, 2017

Paola A. Ascierto, MD, medical oncologist, director of Melanoma Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori “Fondazione G. Pascal,” discusses results of a phase Ib/II dose-escalation study evaluating triple combination therapy with encorafenib, binimetiinib, and ribociclib (Kisquali) in patients with BRAF V600 solid tumors and melanoma.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.